Prime Medicine, Inc. (PRME)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 2.5M 5M 7.5M Q4 '23: 0 Q1 '24: 591K Q2 '24: 591K Q3 '24: 800K Q4 '24: 3M Q1 '25: 3.8M Q2 '25: 5M Q3 '25: 6M Q4 '25: 4.6M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-240M -160M -80M 0 80M 160M 240M Q2 '22: -116.7M Q3 '22: -137.9M Q4 '22: -116.5M Q1 '23: -136.7M Q2 '23: -155.6M Q3 '23: -175.4M Q4 '23: -204.8M Q1 '24: -213.1M Q2 '24: -223.5M Q3 '24: -226.3M Q4 '24: -202.5M Q1 '25: -206.5M Q2 '25: -204.2M Q3 '25: -204M Q4 '25: -208.3M Q1 '26: -206.6M Q2 '26: -196.5M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q4 '21: -165.4M Q1 '22: -102.5M Q2 '22: -132.5M Q3 '22: -145.4M Q4 '22: -121.8M Q1 '23: -137.4M Q2 '23: -150.4M Q3 '23: -171.8M Q4 '23: -198.1M Q1 '24: -204.5M Q2 '24: -217.4M Q3 '24: -219.2M Q4 '24: -195.9M Q1 '25: -202M Q2 '25: -199.3M Q3 '25: -197.3M Q4 '25: -201.1M Q1 '26: -198.4M Q2 '26: -187.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q3 '22: -114.3M Q4 '22: -131.8M Q1 '23: -122.6M Q2 '23: -143.2M Q3 '23: -152.3M Q4 '23: -165.4M Q1 '24: -191.6M Q2 '24: -196.2M Q3 '24: -183M Q4 '24: -122.9M Q1 '25: -104M Q2 '25: -99.9M Q3 '25: -109.1M Q4 '25: -162.6M Q1 '26: -156.4M Q2 '26: -156.1M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Free Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q3 '22: -126M Q4 '22: -147.9M Q1 '23: -139M Q2 '23: -156.8M Q3 '23: -164M Q4 '23: -174.1M Q1 '24: -200.6M Q2 '24: -205.2M Q3 '24: -190.3M Q4 '24: -130.2M Q1 '25: -111.4M Q2 '25: -107M Q3 '25: -115.1M Q4 '25: -167.1M Q1 '26: -158.7M Q2 '26: -156.8M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q3 '21: 15M Q1 '22: 19.1M Q2 '22: 20.2M Q3 '22: 22.2M Q1 '23: 89.1M Q2 '23: 90.5M Q3 '23: 91.8M Q1 '24: 104.5M Q2 '24: 119.2M Q3 '24: 119.8M Q1 '25: 130.9M Q2 '25: 129.2M Q3 '25: 160.5M Q1 '26: 177.1M Q2 '26: 177.2M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q2 '22: -9.31 Q3 '22: -9.40 Q4 '22: -4.19 Q1 '23: -3.05 Q2 '23: -1.76 Q3 '23: -0.70 Q4 '23: -2.18 Q1 '24: -2.18 Q2 '24: -2.17 Q3 '24: -2.06 Q4 '24: -1.65 Q1 '25: -1.61 Q2 '25: -1.56 Q3 '25: -1.44 Q4 '25: -1.37 Q1 '26: -1.25 Q2 '26: -1.08 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.